top of page
Our Mission
Our Programs
Our Approach
Who We Are
News
Contact
More
Use tab to navigate through the menu items.
News
October 1, 2026
MavriX Bio Announces FDA Rare Pediatric Disease Designation for Investigational MVX-220 for the Treatment of Angelman Syndrome
Read More
November 6, 2025
MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
Read More
bottom of page